BELLUS Health Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Roberto Francesco Bellini
- Full Time Employees
- 74
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 275 Armand-Frappier Boulevard Laval QC Canada H7V 4A7
- IPO Date
- Oct 27, 2000
- CIK
- 0001259942
- Website
- bellushealth.com
- Similar Companies
- Business
- BELLUS Health Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of innovative therapeutics for respiratory and other disorders. The company's main products and services include the development of drug candidates such as BLU-5937, a selective P2X3 antagonist for the treatment of refractory or unexplained chronic cough. BELLUS Health also focuses on leveraging its proprietary P2X3 platform to address additional indications related to sensory neuropathic disorders. The company operates primarily in North America and Europe and targets patients suffering from chronic cough and other related medical conditions. Founded in 2010, BELLUS Health is headquartered in Montreal, Canada. In recent major developments, BELLUS Health has advanced the clinical development of BLU-5937, including recent positive clinical trial results that support its efficacy and safety profile. The company has also pursued strategic partnerships to enhance its research capabilities and expand its therapeutic pipeline. In 2024 and 2025, BELLUS Health further refined its strategic focus by prioritizing the commercialization of its lead candidate and exploring additional indications for its P2X3 antagonists. These operational and strategic initiatives underscore the company’s commitment to addressing unmet medical needs in respiratory and sensory disorders, reinforcing its position as a specialized biopharmaceutical enterprise in its market segments.
Bellus Health shareholders say yes to US$2B GSK takeover
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
Alliance Entertainment Reports Third Quarter and Nine Month Fiscal 2023 Financial Results
BELLUS Health Inc. Calls Special Shareholders' Meeting in Connection with GSK Acquisition
BELLUS Santé inc. convoque une assemblée extraordinaire des actionnaires concernant l’acquisition de la société par GSK
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
BELLUS Santé annonce ses résultats financiers et faits saillants pour le premier trimestre de 2023
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
Tommy Hilfiger, Mercedes-AMG PETRONAS Formula One Team e Awake NY lanciano una collaborazione al Grand Prix di Miami
Crackle Connex Showcases Its Unique Advertising and Media Offering at IAB Newfronts
The St. Joe Company Announces the Opening of the 255-suite Embassy Suites by Hilton Panama City Beach Resort
BELLUS Health Announces Meeting Updates
BELLUS Santé annonce de l’information récente au sujet de l’assemblée
BELLUS Health Announces Meeting Updates
Was This Acquisition a Savvy Play by This Big Pharma Stock?
Why Shares of Bellus Health Skyrocketed This Week
Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK
Biopharma stock soars on takeover deal plus more daily small cap and micro cap movers
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
Why BELLUS Health Stock Is Rocketing Higher Today